In a nutshell This trial was carried out to examine the effectiveness of pembrolizumab (Keytruda) consolidation therapy for patients with stage III unresectable non-small cell lung cancer (NSCLC) following a course of chemotherapy and radiation therapy. The authors found that pembrolizumab consolidation improved the outcomes of...
Read More
In a nutshell This study was conducted to assess the safety and patient reported outcomes (PRO) of the addition of atezolizumab (Tecentriq) to chemotherapy with and without bevacizumab (Avastin) vs bevacizumab plus chemotherapy in the treatment of nonsquamous non-small cell lung cancer (NSCLC). The addition...
Read More
In a nutshell This article looked at the effectiveness of gefitinib (Iressa) combined with chemotherapy when compared to a chemotherapy aline in the treatment of non-small cell lung cancer (NSCLC). The authors found that the addition of gefitinib to a chemotherapy increased the progression-free survival (PFS) of these...
Read More
In a nutshell This trial is aiming to examine the effectiveness and safety of atezolizumab (Tecentriq) and tiragolumab compared to durvalumab (Imfinzi) in stage III non-small-cell lung cancer (NSCLC) that cannot be surgically removed and has previously been treated with concurrent (at the same time) platinum-based chemoradiation therapy (CRT)....
Read More
In a nutshell The study evaluated outcomes of brigatinib (Alunbrig) versus crizotinib (Xalkori) in patients with non-small cell lung carcinoma (NSCLC) and anaplastic lymphoma kinase (ALK) mutations, who were previously not treated with ALK inhibitors (ALKI). The main finding was that brigatinib had better long-term outcomes compared to crizotinib in such...
Read More
In a nutshell This trial is being carried out to assess the effectiveness of atezolizumab (Tecentriq) in combination with cabozantinib (Cabometyx) versus docetaxel (Taxotere) in patients with metastatic non-small cell lung cancer (NSCLC) which has previously been treated with immunotherapy and platinum-based chemotherapy....
Read More
In a nutshell This trial is being carried out to assess whether osimertinib (Tagrisso) should be used alone or with chemotherapy for lung cancer and abnormalities (mutations) in the EGFR gene. The main outcome that will be measured in this trial is survival without progression of the disease. This trial will take place in New Jersey and New...
Read More
In a nutshell This study is looking to examine the effectiveness of durvalumab (Imfinzi) and consolidation stereotactic body radiation therapy (SBRT) after chemoradiation for locally advanced stage III non-small-cell lung cancer (NSCLC). The main outcomes to be measured are the occurrence of side effects and the survival without cancer...
Read More
In a nutshell This trial was carried out to assess the effectiveness of anlotinib (AL3818) on different subtypes of non-small cell lung cancer (NSCLC). The trial demonstrated that anlotinib improved progression-free survival (PFS) and overall survival (OS) in patients with adenocarcinoma (ACC) and tended to improve survival in...
Read More
In a nutshell The study evaluated treatment outcomes reported by patients with metastatic non-small-cell lung cancer (mNSCLC) who were treated by pembrolizumab (Keytruda) and pemetrexed (Alimta) and platinum chemotherapy. The authors found that adding pembrolizumab to pemetrexed-platinum chemotherapy improved health-related quality of life (HRQOL)...
Read More
In a nutshell This trial is examining the effectiveness of atezolizumab (Tecentriq) plus carboplatin (Paraplatin) and etoposide (Etopophos) with or without tiragolumab in patients with untreated extensive-stage small-cell lung cancer (ES-SCLC). The main outcomes that will be measured are progression-free survival (PFS) and overall survival...
Read More
In a nutshell This study aimed to look at how statin (a type of cholesterol-lowering medication) use affected the outcomes of patients with lung cancer. This study found that statin use was associated with significantly improved survival in these patients. Some background Lung cancer is one of the most common forms of cancer worldwide....
Read More
